Several publishers have been in the press lately with authors claiming they neither gave permission, nor received payment, for their content being licensed for GenAI.
Information managers have always been at the forefront of IP and copyright risk mitigation and there is a heightened reputational risk that IP owners might target buyers of these services.
Jinfo recommends a proactive approach by incorporating mitigations as part of your supplier due diligence and contracting processes.
Our article "How can you mitigate the risk of infringing authors’ rights with GenAI?" provides analysis and the practical actions you can take to mitigate this risk at source. Read.
Another long-recognised risk is eavesdropping Internet activity.
Now a new vendor is using AI to process vast amounts of eavesdropping data to "predict" corporate actions.
This is a wake-up call for information managers to review the security of your connections with third party content providers.
Read the Jinfo report "Eavesdropping risk-mitigation plan and vendor case study" for our 12-point action plan to mitigate this risk. Read.
Other recent Jinfo articles:
Upcoming Jinfo Community sessions:
- "AI Roundtable" (24th October) – a lot has happened since our roundtable in February, so join your peers in this session to share your AI implementation progress, insights and obstacles. Register.
- "Asia-Pacific" (6th November) – these sessions are timed for Jinfo subscribers in the Asia-Pacific region, and are being really well attended and received. We discuss our latest research and outputs, and close the divide between time-zones. Register.
- "The future of news provision" (19th November). Save the date, details to follow. Register now.
So, lots of great reasons to take out a Jinfo Subscription, if you’re not already a subscriber. Remember, if you have a bit of budget left, "use it or lose it". Find out more or schedule 30 minutes with me.
End-user training in pharma
Finally, we're working with a number of Jinfo clients on a research project covering vendor training for end users in the pharma sector. To find out more or participate, contact me or set up a call.
